TrialCritical care medicine2026

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Madiha Hashmi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.